PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Zheng, J.* ; Wheeler, E.* ; Pietzner, M.* ; Andlauer, T.F.M.* ; Yau, M.S.* ; Hartley, A.E.* ; Brumpton, B.M.* ; Rasheed, H.* ; Kemp, J.P.* ; Frysz, M.* ; Robinson, J.* ; Reppe, S.* ; Prijatelj, V.* ; Gautvik, K.M.* ; Falk, L.* ; Maerz, W.* ; Gergei, I.* ; Peyser, P.A.* ; Kavousi, M.* ; de Vries, P.S.* ; Miller, C.L.* ; Bos, M.* ; van der Laan, S.W.* ; Malhotra, R.* ; Herrmann, M.* ; Scharnagl, H.* ; Kleber, M.* ; Dedoussis, G.* ; Zeggini, E. ; Nethander, M.* ; Ohlsson, C.* ; Lorentzon, M.* ; Wareham, N.* ; Langenberg, C.* ; Holmes, M.V.* ; Davey Smith, G.* ; Tobias, J.H.*

Lowering of circulating sclerostin may increase risk of atherosclerosis and its risk factors: Evidence from a genome-wide association meta-analysis followed by Mendelian randomization.

Arthritis Rheum. 75, 1781-1792 (2023)
Verlagsversion DOI PMC
Open Access Hybrid
Creative Commons Lizenzvertrag
OBJECTIVE: In this study, we aimed to establish the causal effects of lowering sclerostin, target of the antiosteoporosis drug romosozumab, on atherosclerosis and its risk factors. METHODS: A genome-wide association study meta-analysis was performed of circulating sclerostin levels in 33,961 European individuals. Mendelian randomization (MR) was used to predict the causal effects of sclerostin lowering on 15 atherosclerosis-related diseases and risk factors. RESULTS: We found that 18 conditionally independent variants were associated with circulating sclerostin. Of these, 1 cis signal in SOST and 3 trans signals in B4GALNT3, RIN3, and SERPINA1 regions showed directionally opposite signals for sclerostin levels and estimated bone mineral density. Variants with these 4 regions were selected as genetic instruments. MR using 5 correlated cis-SNPs suggested that lower sclerostin increased the risk of type 2 diabetes mellitus (DM) (odds ratio [OR] 1.32 [95% confidence interval (95% CI) 1.03-1.69]) and myocardial infarction (MI) (OR 1.35 [95% CI 1.01-1.79]); sclerostin lowering was also suggested to increase the extent of coronary artery calcification (CAC) (β = 0.24 [95% CI 0.02-0.45]). MR using both cis and trans instruments suggested that lower sclerostin increased hypertension risk (OR 1.09 [95% CI 1.04-1.15]), but otherwise had attenuated effects. CONCLUSION: This study provides genetic evidence to suggest that lower levels of sclerostin may increase the risk of hypertension, type 2 DM, MI, and the extent of CAC. Taken together, these findings underscore the requirement for strategies to mitigate potential adverse effects of romosozumab treatment on atherosclerosis and its related risk factors.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
13.300
0.000
2
1
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Ld Score Regression; Susceptibility Loci; Romosozumab; Identification; Imputation; Frequency; Variants; Women
Sprache englisch
Veröffentlichungsjahr 2023
HGF-Berichtsjahr 2023
ISSN (print) / ISBN 0004-3591
e-ISSN 1529-0131
Zeitschrift Arthritis & Rheumatology
Quellenangaben Band: 75, Heft: 10, Seiten: 1781-1792 Artikelnummer: , Supplement: ,
Verlag Wiley
Verlagsort 111 River St, Hoboken 07030-5774, Nj Usa
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Translational Genomics (ITG)
POF Topic(s) 30205 - Bioengineering and Digital Health
Forschungsfeld(er) Genetics and Epidemiology
PSP-Element(e) G-506700-001
Förderungen European Research Area Network on Cardio-vascular Diseases (ERA-CVD) program" druggable-MI-targets"
Leducq Foundation"PlaqOmics"
National Heart, Lung, and Blood Institute(NHLBI), NIH
National Key Research and Development Program of China
Wellcome Trust
UK Medical Research Council
University of Bristol
NIH
Netherlands CardioVascular Research Initiative of the Netherlands Heart Foundation
Wild Family Foundation
American Heart Association
NHLBI, NIH
EU Horizon 2020 project TO_AI-TION
NHLBI
National Health and Medical Research Council (Australia) investigator grant
St. Olav's Hospital
Liaison Committee for Education, Research and Innovation in Central Norway
Research Council of Norway
University of Michigan
Faculty of Medicine and Health Sciences, NTNU
DOI 10.1002/art.42538
WOS ID 001042834400001
Scopus ID 85165626416
PubMed ID 37096546
Erfassungsdatum 2023-10-06
[➜Korrektur melden]